^
Association details:
Biomarker:NFE2L2 mutation
Cancer:Solid Tumor
Drug:IPN60090 (Glutaminase inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Excerpt:
...Patients with tumors harboring actionable KEAP1/NFE2L2/STK11/NF1 mutations Patients with low ASNS expression levels (HGSOC or endometrial cancer) Patients who had immunotherapy (IO) melanoma (Minimum treatment duration of prior PD-1 or PD-L1-containing regimen of 12 weeks [or equivalent of 2 response evaluations])....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

New Therapy for Lung and Ovarian Cancer Advances to Early-stage Clinical Development

Published date:
04/27/2020
Excerpt:
IPN60090 currently is under investigation in a Phase I dose-escalation and dose-expansion study for patients with advanced solid tumors that harbor KEAP1/NFE2L2 mutations or have low ASNS levels. Initial data from the clinical trial indicate that IPN60090 is effectively inhibiting GLS1 activity in peripheral blood.mononuclear cells from patients.